Avid Bioservices Inc (CDMO)

[technicalwin]

Hey Braingraft, saw your 2C3 post over on RB. Really doing your homework. Here we are 2 years post the May 20,2003 PR and little has been done with 2C3. Apparently, PPHM believes that Tarvacin is a much better drug. After reading the 10-Q, I hope SK did not list in order their priorities for future R&D. I hate to see Cotara becoming important again. It is clear to me that 3G4 viral should be getting the most attention after Tarvacin cancer. That way we can leverage the P1 results. Obviously, they have to follow through on the Cotara/NCI project, but resourses are limited. Seems like a DNA competitor should be interested in a license for 2C3. TW